Study progress on anti-tuberculosis drug-induced liver damage associated with drug-metabolizing enzyme gene polymorphism

Abstract

Abstract: Tuberculosis is a chronic infectious disease caused by mycobacterium and is one of the serious infectious diseases harmful to human health. Anti-tuberculosis drug-induced hepatotoxicity (ATDH) draws more attention in the treatment of tuberculosis recently. It is worthy of summarizing the detailed mechanism about ATDH which is still not clear today. It is known to us that anti-tuberculosis drugs are formed less toxic metabolite in vivo by various metabolic enzymes and transporters, and the polymorphisms of transporters and enzymes are likely to be the important factors associated with ATDH. This paper provides an overview about the correlation between drug metabolic enzymes polymorphisms and ATDH.

Key words: ATDH, anti-tuberculosis drug, drug metabolic enzymes, drug transporters, polymorphism

CLC Number:

R968

LIU Yu, GAO Rui, CHEN Yu, CHEN Lin, XIA Chun-hua, DENG Guo-fang. Study progress on anti-tuberculosis drug-induced liver damage associated with drug-metabolizing enzyme gene polymorphism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 91-95.

References

[1] Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers [J]. Am J Respir Crit Care Med, 2001, 164(7): 1112-1113.
[2] Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis [J]. Am J Respir Crit Care Med, 2003, 167(7): 1472-1477.
[3] Lee SW, Chung LS, Huang HH, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis [J]. Int J Tuberc Lung Dis, 2010, 14(5): 622-626.
[4] Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis [J]. J Gastroenterol Hepatol, 2011, 26(2): 312-318.
[5] Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury [J]. J Hepatol, 2007, 47(1): 128-134.
[6] Vavricka SR, Van Montfoort J, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver [J]. Hepatology, 2002, 36(1): 164-172.
[7] Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes [J]. Lancet, 2000, 356(9241): 1587-1591.
[8] Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man [J]. J Pharmacokinet Biopharm, 1976, 4(2): 83-113.
[9] Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity [J]. Respirology, 2006, 11(6): 699-707.
[10] Morel G, Cossec B, Lambert AM, et al. Evaluation of rat hepatic 2E1 activity in function of age, sex and inducers: choice of an experimental model capable of testing the hepatotoxicity of low molecular weight compounds [J]. Toxicol Lett, 1999, 106(2): 171-180.
[11] 崔金霞, 关巍, 冯喜英. N 乙酰化转移酶 2 基因多态性与异烟肼所致肝损伤研究进展[J]. 中国医疗前沿, 2013, 8(9): 16-18.
[12] Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity [J]. Pharmacogenomics, 2008, 9(3): 311-321.
[13] 郝金奇, 陈怡, 李世明, 等. 尿苷二磷酸葡糖醛酸转移酶1A6基因多态性与抗结核药物致肝损害的相关性[J]. 中国肝脏病杂志, 2011, 19(3): 201-204.
[14] Jamis-Dow CA, Katki AG, Collins JM, et al. Rifampin and rifabutin and their metabolism by human liver esterases [J]. Xenobiotica, 1997, 27(10): 1015-1024.
[15] McCarty MF. ''Iatrogenic Gilbert syndrome''-A strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin [J]. Med Hypotheses, 2007, 69(5): 974-994.
[16] Oelberg DG, Lester R. Cellular mechanisms of cholestasis [J]. Annu Rev Med, 1986, 37(1): 297-318.
[17] Nelson SD, Mitchell JR, Timbrell JA, et al. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat [J]. Science, 1976, 193(4256): 901-903.
[18] Mitchel JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione [J]. J Pharmacol Exp Ther, 1973, 187(1): 211-217.
[19] Tsutsumi M, Takada A, Wang JS. Genetic polymorphism of cytochrome P-450 2E1 related to the development of alcoholic liver disease [J]. Gastroenterology, 1994, 107(5): 1430-1435.
[20] Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis [J]. Hepatology, 2003, 37(4): 924-930.
[21] Vuilleurnier N, Rossier MF, Chiappe A, et al. CYP2El genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis [J]. Eur J Clin Phamacol, 2006, 62(6): 423-429.
[22] 王涛, 王巍, 王仲元, 等. 细胞色素P450-2E1基因多态性与抗结核药物性肝损害的相关性[J]. 中华结核和呼吸杂志, 2009, 32(8): 585-587.
[23] 吴雪琼, 朱冬林, 张俊仙,等. 羧酸酯酶基因1多态性鉴定及其与抗结核药物肝毒性相关性研究[J]. 中华内科杂志, 2012, 51(7): 524-530.
[24] Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis [J]. Ann Intern Med, 1976, 84(2): 181-192.
[25] Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients [J]. Int J Tuberc Lung Dis, 2013, 17(4): 499-504.
[26] Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients [J]. Mem Inst Oswaldo Cruz, 2011, 106(6): 716-724.
[27] Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites [J]. Clin Pharmacol Ther, 1975, 18(1): 70-79.
[28] Du H, Chen X, Fang Y, et al. Slow N-acetyltransferase 2 genotype contributes to antituberculosis drug-induced hepatotoxicity: a meta-analysis [J]. Mol Biol Rep, 2013, 40(5): 3591-3596.
[29] 安慧如, 吴雪琼, 王仲元. N-乙酰基转移酶 2 及谷胱甘肽 S 转移酶 M1 基因多态性与抗结核药物性肝损伤的关系研究[J]. 中国防痨杂志, 2014, 36(1): 14-20.
[30] Possuelo LG, lCastclan JA, deyBrito TC, et a1. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil[J]. Eur J Clin Pharmacol, 2008, 64(7): 673-681.
[31] Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity In Japanese patients with tuberculosis [J]. World J Gastroenterol, 2007, 13(45): 6003-6008.
[32] Strang RC, Jones PW, Fryer AA. Glutathione S-transferase: Genetics and role in toxiclogy [J]. 2000, 112-113: 357-363.
[33] Leiro V, Fern'andez-Villar A, Valverde D, et al. Infuence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population [J]. Liver Int, 2008, 28(6): 835-839.
[34] Kim SH, Kim SH, Yoon HJ, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans [J]. Tuberculosis, 2010, 90(1): 39-43.
[35] Tang KS, Lee CM, Teng HC, el a1. UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis [J]. Biochem Biophys Res Commun, 2008, 366(3): 643-648.
[36] 郝金奇, 陈冶, 李世明, 等. 尿苷二磷酸葡萄糖醛酸转移酶1A7基因多态性与抗结核药致肝损伤易感性的关系[J]. 中华传染病杂志, 2012, 30(3): 174-178.
[37] Li M, Zhang YZ. Modulation of gene expression in cholesterol-lowering effect of electroacupuncture at Fenglong acupoint (ST40): a cDNA microarray study [J]. Int J Mol Med, 2007, 19(4): 617-629.
[38] Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations [J]. Antimicrob Agents Chemother, 2010, 54(10): 4192-4200.
[39] Fountain FF, Tolley EA, Jacobs AR, et al. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection [J]. Am J Med Sci, 2009, 337(5): 317-320.
[40] Li LM, Chen L, Deng GH, et al. SLCO1B1*15 haplotype is associated with rifampininduced liver injury [J]. Mol Med Rep, 2012, 6(1): 75-82.